Woodward DF, Wang JW, Stamer WD, Lütjen-Drecoll E, Krauss AHP, Toris CB (2019)
Publication Type: Journal article
Publication year: 2019
For >2 decades, EP2 agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval of the first drug of this class. This article reviews the development of EP2 agonists from conception to clinical approval, discussing pharmacology, structure, biodistribution, therapeutics, and drug delivery. An extensive list of source references is provided for the reader's benefit.
APA:
Woodward, D.F., Wang, J.W., Stamer, W.D., Lütjen-Drecoll, E., Krauss, A.H.-P., & Toris, C.B. (2019). Antiglaucoma EP2 Agonists: A Long Road That Led Somewhere. Journal of Ocular Pharmacology and Therapeutics. https://doi.org/10.1089/jop.2019.0041
MLA:
Woodward, David F., et al. "Antiglaucoma EP2 Agonists: A Long Road That Led Somewhere." Journal of Ocular Pharmacology and Therapeutics (2019).
BibTeX: Download